Prognia
Drug Database
🇪🇺EU · EMAWithdrawn

Evusheld(tixagevimab;cilgavimab)

COVID-19 virus infection

Marketing Authorisation Holder: AstraZeneca AB

EMA Authorisation: 25/03/2022

INN: tixagevimab;cilgavimab

Indication

Prevention of COVID-19.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Evusheld — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.